Published in:
Open Access
01-12-2019 | Liver Transplantation | Research
Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their function
Authors:
Francesca Ulbar, Tiziana Montemurro, Tatiana Jofra, Miriam Capri, Giorgia Comai, Valentina Bertuzzo, Cristiana Lavazza, Alessandra Mandelli, Mariele Viganò, Silvia Budelli, Maria Giulia Bacalini, Chiara Pirazzini, Paolo Garagnani, Valeria Giudice, Daria Sollazzo, Antonio Curti, Mario Arpinati, Gaetano La Manna, Matteo Cescon, Antonio Daniele Pinna, Claudio Franceschi, Manuela Battaglia, Rosaria Giordano, Lucia Catani, Roberto Massimo Lemoli
Published in:
Journal of Translational Medicine
|
Issue 1/2019
Login to get access
Abstract
Background
Here, we isolated, expanded and functionally characterized regulatory T cells (Tregs) from patients with end stage kidney and liver disease, waiting for kidney/liver transplantation (KT/LT), with the aim to establish a suitable method to obtain large numbers of immunomodulatory cells for adoptive immunotherapy post-transplantation.
Methods
We first established a preclinical protocol for expansion/isolation of Tregs from peripheral blood of LT/KT patients. We then scaled up and optimized such protocol according to good manufacturing practice (GMP) to obtain high numbers of purified Tregs which were phenotypically and functionally characterized in vitro and in vivo in a xenogeneic acute graft-versus-host disease (aGVHD) mouse model. Specifically, immunodepressed mice (NOD-SCID-gamma KO mice) received human effector T cells with or without GMP-produced Tregs to prevent the onset of xenogeneic GVHD.
Results
Our small scale Treg isolation/expansion protocol generated functional Tregs. Interestingly, cryopreservation/thawing did not impair phenotype/function and DNA methylation pattern of FOXP3 gene of the expanded Tregs. Fully functional Tregs were also isolated/expanded from KT and LT patients according to GMP. In the mouse model, GMP Tregs from LT or KT patient proved to be safe and show a trend toward reduced lethality of acute GVHD.
Conclusions
These data demonstrate that expanded/thawed GMP-Tregs from patients with end-stage organ disease are fully functional in vitro. Moreover, their infusion is safe and results in a trend toward reduced lethality of acute GVHD in vivo, further supporting Tregs-based adoptive immunotherapy in solid organ transplantation.